CDKN2B and myelodysplastic syndrome: Analysis of a small cohort of 23 myelodysplastic syndrome (MDS) patients with hypermethylated p15INK4B demonstrated a reduction in methylation following one course of low-dose 5-azacytidine and this was associated with clinical response (Daskalakis et al, 2002).